Generation Bio Inc. (GBIO): Price and Financial Metrics


Generation Bio Inc. (GBIO): $6.70

0.14 (+2.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GBIO Stock Price Chart Interactive Chart >

Price chart for GBIO

GBIO Price/Volume Stats

Current price $6.70 52-week high $28.67
Prev. close $6.56 52-week low $3.96
Day low $6.37 Volume 151,900
Day high $6.84 Avg. volume 446,481
50-day MA $6.02 Dividend yield N/A
200-day MA $10.85 Market Cap 382.49M

Generation Bio Inc. (GBIO) Company Bio


Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.


GBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

GBIO Latest Social Stream


Loading social stream, please wait...

View Full GBIO Social Stream

Latest GBIO News From Around the Web

Below are the latest news stories about Generation Bio Co that investors may wish to consider to help them evaluate GBIO as an investment opportunity.

Generation Bio GAAP EPS of -$0.54 beats by $0.03

Generation Bio press release (NASDAQ:GBIO): Q4 GAAP EPS of -$0.54 beats by $0.03. Cash and cash equivalents were $375.1M as of December 31, 2021...

Seeking Alpha | February 24, 2022

Generation Bio Outlines 2022 Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

Well-capitalized with $375.1 million at the end of 2021, funding planned operations into 2024CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2022 and reported fourth quarter and full year 2021 financial results. “Our primary focus is on diseases of the liver, where we are working to complete optimization of our cell-

Yahoo | February 24, 2022

Generation Bio Promotes Antoinette Paone, M.S., MBA to Chief Operating Officer

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Antoinette Paone to chief operating officer (COO). Ms. Paone has served as senior vice president and head of regulatory affairs and quality at Generation Bio since 2018. “Antoinette has made significant contributions to shaping our strategic direction, and her leadership has also

Yahoo | February 10, 2022

Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022. Presentation DetailsDate: Wednesday, Jan. 12, 2022Time: 8:15-8:55 a.m. ET A live webcast of the company presentation and Q&A session will be available on the investor secti

Yahoo | January 5, 2022

SHAREHOLDER ALERT: Robbins LLP Investigates Generation Bio Co. (GBIO) on Behalf of Shareholders

SAN DIEGO, December 29, 2021--Generation Bio Co. (GBIO) Reports Poor Results for Preclinical Studies for Hemophilia A Program

Yahoo | December 29, 2021

Read More 'GBIO' Stories Here

GBIO Price Returns

1-mo 24.77%
3-mo -18.09%
6-mo -13.66%
1-year -74.92%
3-year N/A
5-year N/A
YTD -5.37%
2021 -75.03%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7034 seconds.